HUMAN PLASMA is a source material that is crucial for the production of unique therapeutic fractionated products.Indeed,plasma contains hundreds of proteins ensuring many physiological functions.The most abundant pro...HUMAN PLASMA is a source material that is crucial for the production of unique therapeutic fractionated products.Indeed,plasma contains hundreds of proteins ensuring many physiological functions.The most abundant proteins,albumin and immunoglobulin G (IgG),are present at about 35 and 10 g/L,respectively,representing about 80% of all plasma proteins.However,other important therapeutic proteins include the coagulation factors (factor Ⅷ (FⅧ); FⅨ; Von Willebrand Factor (VWF),fibrinogen) various protease inhibitors (alpha 1-antitrypsin; antithrombin; C1-esterase) and anticoagulants (protein C) which exhibit potent physiological activity.Currently over 10 different protein therapeutics can be extracted from plasma to treat life-threatening diseases or injuries associated to bleeding and thrombotic disorders,immunological diseases,infectious conditions as well as tissue degenerating diseases,thus addressing the clinical needs of many patients.Considering that plasma is a very valuable resources available in limited supply at national levels,it is important,for ethical,medical,and economical reasons,to optimize its use by producing,at satisfactory yields,an appropriate range of safe products meeting the needs of patients.展开更多
Objective: To evaluate the efficiency of Coleman lipostructure in patients infected with human immunodeficiency virus (HIV). Design: Open-label study and survey. Setting: Ambulatory dermatosurgery department of a univ...Objective: To evaluate the efficiency of Coleman lipostructure in patients infected with human immunodeficiency virus (HIV). Design: Open-label study and survey. Setting: Ambulatory dermatosurgery department of a university hospital. Patients: Thirty-three consecutive HIV-infected patients undergoing Coleman lipostructure between 2000 and 2001. Interventions: Clinical examination,blood tests, and standardized photographs at baseline and 1 year after the lipostructure. Me an Outcome Measures: Efficiency was assessed by the agreement of 3 independent m edical specialists on facial lipodystrophy improvement after surgery and by patient satisfaction. Results: Facial lipoatrophy was improved in 12 patients (36%; 95%confidence interval, 20%-52%) as judged by all 3 evaluators. Quantity of fat injected (P=.01) and a low serum triglyceride level before surgery (P=.03) were significantly associated with improvement of facial lipoatrophy. Of the 33 patients, 14 (43%) were very satisfied, 17 (50%) were partly satisfied, and 27 (81%) had a better quality of life. The most common comment was that the patie nt looked better and appeared less ill. Conclusion: Our 1-year evaluation of Coleman lipostructure for correction of facial lipoatrophy in HIV-infected patien ts proved the efficiency of this treatment when measured conservatively by agree ment on improvement by 3 independent specialists and demonstrated a patient satisfaction rate of 93%.展开更多
文摘HUMAN PLASMA is a source material that is crucial for the production of unique therapeutic fractionated products.Indeed,plasma contains hundreds of proteins ensuring many physiological functions.The most abundant proteins,albumin and immunoglobulin G (IgG),are present at about 35 and 10 g/L,respectively,representing about 80% of all plasma proteins.However,other important therapeutic proteins include the coagulation factors (factor Ⅷ (FⅧ); FⅨ; Von Willebrand Factor (VWF),fibrinogen) various protease inhibitors (alpha 1-antitrypsin; antithrombin; C1-esterase) and anticoagulants (protein C) which exhibit potent physiological activity.Currently over 10 different protein therapeutics can be extracted from plasma to treat life-threatening diseases or injuries associated to bleeding and thrombotic disorders,immunological diseases,infectious conditions as well as tissue degenerating diseases,thus addressing the clinical needs of many patients.Considering that plasma is a very valuable resources available in limited supply at national levels,it is important,for ethical,medical,and economical reasons,to optimize its use by producing,at satisfactory yields,an appropriate range of safe products meeting the needs of patients.
文摘Objective: To evaluate the efficiency of Coleman lipostructure in patients infected with human immunodeficiency virus (HIV). Design: Open-label study and survey. Setting: Ambulatory dermatosurgery department of a university hospital. Patients: Thirty-three consecutive HIV-infected patients undergoing Coleman lipostructure between 2000 and 2001. Interventions: Clinical examination,blood tests, and standardized photographs at baseline and 1 year after the lipostructure. Me an Outcome Measures: Efficiency was assessed by the agreement of 3 independent m edical specialists on facial lipodystrophy improvement after surgery and by patient satisfaction. Results: Facial lipoatrophy was improved in 12 patients (36%; 95%confidence interval, 20%-52%) as judged by all 3 evaluators. Quantity of fat injected (P=.01) and a low serum triglyceride level before surgery (P=.03) were significantly associated with improvement of facial lipoatrophy. Of the 33 patients, 14 (43%) were very satisfied, 17 (50%) were partly satisfied, and 27 (81%) had a better quality of life. The most common comment was that the patie nt looked better and appeared less ill. Conclusion: Our 1-year evaluation of Coleman lipostructure for correction of facial lipoatrophy in HIV-infected patien ts proved the efficiency of this treatment when measured conservatively by agree ment on improvement by 3 independent specialists and demonstrated a patient satisfaction rate of 93%.
